The recommended intake level for Ubiquinol can be found on the product packaging. But how are these levels determined? Kaneka uses data from human studies, which point to an intake level of 100-300 mg per day. Let's understand how that works.
The kind of study that is used is called a pharmacokinetic study (it can also be called a bioavailability study). It measures the amount of a supplement or its metabolites (that is, the byproduct of the body breaking down the supplement) that can be found in the blood after ingestion. Here's the procedure: a group of subjects takes a certain level of a supplement daily for a given period of time (called a chronic study). Blood is taken both at the beginning, before any supplement intake, and at certain intervals after intake to measure how much of the supplement is in the blood. Blood levels can be measured over a period of weeks. This typ of study has helped determine the intake level for Ubiquinol.
In the studies of Ubiquinol, what was found in the blood was the Ubiquinol itself, rather than a metabolite. This made it easy to relate the amount that is ingested with what is available for the body to use.
Three studies have measured the blood levels of Ubiquinol after its ingestion by healthy people, all using KanekaQH™ Ubiquinol. In the most extensive study using KanekaQH1 performed by Hosoe et al. in 2007, three intake levels were used: 90, 150, and 300 mg per day. The supplement was taken twice a day (for example 45 mg at both breakfast and dinner for a 90 mg per day total intake). There were 20 subjects for each intake level, for a total of 60 subjects. This was done for four weeks, and the blood levels were measured at the start of the study (before any intake of supplement) and at two and four weeks after starting the supplement. All three intake levels showed significant increases from initial levels at both two and four weeks. At four weeks, blood levels were 5.0-, 5.9- and 11.1-fold greater for 90, 150, and 300 mg intake levels, respectively. One would expect that the more Ubiquinol the subjects took, the more would end up in the blood, and that is exactly what happened.
What the Hosoe et al. study also revealed was that the amount of Ubiquinol in the blood built up steadily for the first two weeks, but plateaued between two and four weeks. This is why a higher intake level of Ubiquinol is recommended in the first two to three weeks to help bring blood levels up initially, which can then be lowered thereafter to maintain blood levels.
Another study used 100 mg per day in 11 subjects for six months and found an average increase of 3.9 mg of Ubiquinol in the blood,2 while a third study tested 150 mg per day in 53 subjects for two weeks and found an increase of 4.8-fold above initial levels.3
Having such increases of Ubiquinol in the blood after Ubiquinol supplementation provides evidence that when taking Ubiquinol at the levels tested, namely 100-300 mg/day, the body has sufficient amounts available to use. This is especially important for a number of populations, such as those on statin drugs, who can benefit from the nutritional support supplied by Ubiquinol to help maintain a healthy CoQ10 balance during statin use (see the post, "How the Use of Statins Can Affect Your Coenzyme Q10 Levels"). In addition, it can also be helful to older adults, who have been shown to have lower levels of Ubiquinol in their blood;4 and people with certain conditions which may be associated with lower blood levels of Ubiquinol.
For information on intake levels that are right for you, the best first step is always to consult your doctor.
- Hosoe K, Kitano M, Kishida H, Kubo H, Fujii K, Kitahara M. Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol. 2007 Feb;47(1):19-28.
- Shoko D, Fujii K, Kurihara T. The effect of the reduced form of coenzyme Q10 (Ubiquinol, Kaneka QH™ ) on QOL improvement in the elderly. J Clin Therap Med 2008; 24:233-238.
- Schmelzer C, Niklowitz P, Okun JG, Haas D, Menke T, Döring F. Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans. IUBMB Life. 2011 Jan;63(1):42-8.
- Wada H, Goto H, Hagiwara S, Yamamoto Y. Redox status of coenzyme Q10 is associated with chronological age. J Am Geriatr Soc. 2007 Jul;55(7):1141-2.
This article is for general educational purposes only and is not intended to be used as or substituted for medical advice. Always seek the advice of your physician or qualified health care provider with any questions about your health or a medical condition. Never disregard or delay seeking medical advice because of something you have read on the internet.